Research Article

Leukocyte Count as Chronic Inflammation Markers in Type 2 Diabetes Patients

Volume: 17 Number: 4 December 20, 2017
  • Esra Durmuş
  • Cenk Aypak *
  • Süleyman Görpelioğlu
EN TR

Leukocyte Count as Chronic Inflammation Markers in Type 2 Diabetes Patients

Abstract

Objectives: Epidemiological studies have revealed an association between higher total peripheral white blood cells (WBC) count and Type 2 Diabetes Mellitus (T2DM). However, the association has not been systematically investigated. The aim of this study was to compare peripheral leukocyte count and biochemical test results in diabetic and non–diabetic patients.
Materials and Methods: The study was conducted among the patients had been followed by Family Medicine Outpatient Clinics of Dışkapı Yıldırım Beyazıt Training and Research Hospital between 02.02.2015-30.09.2015. Patients anthropometric measurements, complete blood cell count and biochemical tests’ results were recorded and these values were compared between two groups (T2DM(+) and T2DM(-)).
Results: A total of 286 patients (mean age: 58.7±10.5 years) were enrolled. There were no differences in age and sex distribution between T2DM(+) (n=108) and T2DM (-) (n=178) groups. In T2DM(+) group, leukocyte count was found to be higher than T2DM(-) group (7.73 × 103/ml; 7.17 × 103/ml; p=0.001). Waist circumference, body mass index, fasting blood glucose, alanine amino transferase and triglycerides levels were also found to significantly higher in T2DM(+) group. Conversly, high density lipoprotein and low-density lipoprotein levels were found to be significantly lower in T2DM(+) group. 
Conclusion: Leukocyte count, even within normal range, was higher in T2DM patients compared to non-diabetic individuals. Our results support the role of chronic inflammation in T2DM. There is a need for comprehensive studies to explain the role of inflammation in diabetes.

Keywords

References

  1. 1. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286(3):327–34.
  2. 2. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11(2):98–107.
  3. 3. Odegaard Jl, Chawla A. PleiotropicActions of Insulin Resistance and Inflammation in Metabolic Homeostasis. Science 2013;339(6116):172-7.
  4. 4. Gkrania-Klotsas E, Ye Z, Cooper AJ, et al. Differential White blood cell count and type 2 diabetes: systematic review and meta-analysis of cross-sectional and prospective studies. PloSone 2010;5(10):13405.
  5. 5. Kılıçlı MF, Acıbucu F. Chronic Inflammation, Insulin Resistance and Diabetes. Turkiye Klinikleri J Pharmacol- Special Topics 2015;3(3):30-5.
  6. 6. Yudkin JS, Juhan-Vague I, Hawe E, et al. Low grade inflammation may play a role in the etiology of metabolic syndrome in patients with coronary heart disease: HIFMECH study. Metabolism 2004;53:852–7.
  7. 7. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999;353(9165):1649–52.
  8. 8. Nilsson J, Jovinge S, Niemann A, Reneland R, Lithell H. Relation between plasma tumor necrosis factor-alpha and insülin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arteriosclerosis, thrombosis, and vascular biology 1998;18(8):1199–202.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Authors

Esra Durmuş This is me

Süleyman Görpelioğlu This is me

Publication Date

December 20, 2017

Submission Date

May 10, 2017

Acceptance Date

November 30, 2017

Published in Issue

Year 2017 Volume: 17 Number: 4

APA
Durmuş, E., Aypak, C., & Görpelioğlu, S. (2017). Leukocyte Count as Chronic Inflammation Markers in Type 2 Diabetes Patients. Ankara Medical Journal, 17(4), 253-259. https://doi.org/10.17098/amj.364164
AMA
1.Durmuş E, Aypak C, Görpelioğlu S. Leukocyte Count as Chronic Inflammation Markers in Type 2 Diabetes Patients. Ankara Med J. 2017;17(4):253-259. doi:10.17098/amj.364164
Chicago
Durmuş, Esra, Cenk Aypak, and Süleyman Görpelioğlu. 2017. “Leukocyte Count As Chronic Inflammation Markers in Type 2 Diabetes Patients”. Ankara Medical Journal 17 (4): 253-59. https://doi.org/10.17098/amj.364164.
EndNote
Durmuş E, Aypak C, Görpelioğlu S (December 1, 2017) Leukocyte Count as Chronic Inflammation Markers in Type 2 Diabetes Patients. Ankara Medical Journal 17 4 253–259.
IEEE
[1]E. Durmuş, C. Aypak, and S. Görpelioğlu, “Leukocyte Count as Chronic Inflammation Markers in Type 2 Diabetes Patients”, Ankara Med J, vol. 17, no. 4, pp. 253–259, Dec. 2017, doi: 10.17098/amj.364164.
ISNAD
Durmuş, Esra - Aypak, Cenk - Görpelioğlu, Süleyman. “Leukocyte Count As Chronic Inflammation Markers in Type 2 Diabetes Patients”. Ankara Medical Journal 17/4 (December 1, 2017): 253-259. https://doi.org/10.17098/amj.364164.
JAMA
1.Durmuş E, Aypak C, Görpelioğlu S. Leukocyte Count as Chronic Inflammation Markers in Type 2 Diabetes Patients. Ankara Med J. 2017;17:253–259.
MLA
Durmuş, Esra, et al. “Leukocyte Count As Chronic Inflammation Markers in Type 2 Diabetes Patients”. Ankara Medical Journal, vol. 17, no. 4, Dec. 2017, pp. 253-9, doi:10.17098/amj.364164.
Vancouver
1.Esra Durmuş, Cenk Aypak, Süleyman Görpelioğlu. Leukocyte Count as Chronic Inflammation Markers in Type 2 Diabetes Patients. Ankara Med J. 2017 Dec. 1;17(4):253-9. doi:10.17098/amj.364164

Cited By